Health Care • Medical Specialities
$8.70 ▲ +0.30
(+3.57%)
MKT CAP: $210.8M • VOL: 378.4K
52W L $3 52W H $12
XGN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $66.6M | $55.6M | $52.5M |
| YoY Revenue Growth % | +19.7% | +5.9% | — |
| Gross Profit | $38.8M | $33.1M | — |
| Gross Margin % | 58.3% | 59.5% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$14.1M | -$13.6M | -$22.8M |
| Operating Margin % | -21.1% | -24.5% | -43.5% |
| Net Income (GAAP) | -$20.0M | -$15.1M | -$23.7M |
| EBITDA (Normalized) | -$13.6M | -$13.2M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$13.6M | -$13.3M | -$14.5M |
| Capital Expenditures (CapEx) | $641.0K | $515.0K | — |
| Free Cash Flow (FCF) | -$14.3M | -$13.8M | -$14.5M |
| FCF Margin % | -21.4% | -24.8% | -27.5% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $32.2M | $22.0M | — |
| Total Debt (Short + Long Term) | $22.3M | $19.8M | — |
| Total Stockholders' Equity | $17.4M | $9.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR XGN.